Bone loss and inhaled glucocorticoids.

Bone loss and inhaled glucocorticoids.

Detalhes bibliográficos
Main Authors:	van Staa, T, Leufkens, B, Cooper, C
Formato:	Journal article
Idioma:	English
Publicado em:	2002

Registos relacionados

Inhaled corticosteroids and risk of fractures
Por: Van Staa, T, et al.
Publicado em: (2000)

Use of inhaled corticosteroids and risk of fractures.
Por: van Staa, T, et al.
Publicado em: (2001)

Inhaled corticosteroids and hip fracture: disease or drugs?
Por: van Staa, T, et al.
Publicado em: (2003)

Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study.
Por: de Vries, F, et al.
Publicado em: (2007)

Are inhaled corticosteroids associated with an increased risk of fracture in children?
Por: van Staa, T, et al.
Publicado em: (2004)

The use of inhaled corticosteroids is not associated with an increased risk of fracture in children.
Por: van Staa, T, et al.
Publicado em: (2001)

CUMULATIVE RISKS OF FRACTURE IN PATIENTS USING ORAL GLUCOCORTICOIDS
Por: Van Staa, T, et al.
Publicado em: (2004)

Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.
Por: van Staa, T, et al.
Publicado em: (2007)

Fracture risk with intermittent high-dose oral glucocorticoid therapy.
Por: De Vries, F, et al.
Publicado em: (2007)

A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids.
Por: van Staa, T, et al.
Publicado em: (2005)

Inhaled corticosteroids and hip fracture: Disease or drugs? [2] (multiple letters)
Por: Van Staa, T, et al.
Publicado em: (2003)

Inhaled glucocorticoids and COPD exacerbations.
Por: Brightling, C, et al.
Publicado em: (2015)

The value of bone turnover markers in the prediction of vertebral fracture in patients using oral glucocorticoids.
Por: van Staa, T, et al.
Publicado em: (2003)

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
Por: Van Staa, T, et al.
Publicado em: (2003)

Public health impact of adverse bone effects of oral corticosteroids.
Por: van Staa, T, et al.
Publicado em: (2001)

Periarticular bone loss in arthritis: Role of synovial glucocorticoid generation
Por: Cooper, MS, et al.
Publicado em: (2010)

Paget's disease of the bone in general clinical practice.
Por: van Staa, T, et al.
Publicado em: (2000)

Incidence and natural history of Paget's disease of bone in England and Wales.
Por: van Staa, T, et al.
Publicado em: (2002)

Cell Transitions Contribute to Glucocorticoid-Induced Bone Loss
Por: Xiaojing Qiao, et al.
Publicado em: (2023-07-01)

Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations
Por: McKeever, T, et al.
Publicado em: (2018)

Does a fracture at one site predict later fractures at other sites? A British cohort study.
Por: van Staa, T, et al.
Publicado em: (2002)

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.
Por: van Staa, T, et al.
Publicado em: (2002)

Utility of medical and drug history in fracture risk prediction among men and women.
Por: van Staa, T, et al.
Publicado em: (2002)

Use of nonsteroidal anti-inflammatory drugs and risk of fractures.
Por: van Staa, T, et al.
Publicado em: (2000)

The estimation of cost-effectiveness thresholds prior to the start of large clinical studies
Por: Van Staa, T, et al.
Publicado em: (2006)

Diseases and drugs associated with osteoporosis predict fractures at different sites
Por: van Staa, T, et al.
Publicado em: (2001)

Is persistence to bisphosphonate therapy related only to dosing regimen?
Por: van Staa, T, et al.
Publicado em: (2006)

Does a fracture at one site predict later fractures at any other site?
Por: van Staa, T, et al.
Publicado em: (2001)

The limitations of using simple definitions of glucocorticoid exposure on the prediction of fracture risk
Por: Robinson, D, et al.
Publicado em: (2018)

PREDICTORS FOR VERTEBRAL FRACTURES AND FRACTURE THRESHOLD IN PATIENTS USING ORAL GLUCOCORTICOIDS
Por: van Staa, T, et al.
Publicado em: (2003)

Inhaled Glucocorticoid Use and the Risk of Osteoporosis in Asthmatic Patients
Por: Mojtaba Eizadi, et al.
Publicado em: (2017-11-01)

Glucocorticoid-Induced Bone Loss Is Associated with Abnormal Intravertebral Areal Bone Mineral Density Distribution
Por: Louise I. Manning, et al.
Publicado em: (2013-01-01)

Risk of Fracture and Bone Mineral Density in Stroke Response
Por: Pouwels, S, et al.
Publicado em: (2010)

The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: a cohort study
Por: Robinson, D, et al.
Publicado em: (2018)

Therapeutic glucocorticoids prevent bone loss but drive muscle wasting when administered in chronic polyarthritis
Por: C. G. Fenton, et al.
Publicado em: (2019-08-01)

Glucocorticoids: A review of its adverse effects including bone loss
Por: Amit Dua, et al.
Publicado em: (2019-01-01)

Role of glucocorticoid-induced leucine zipper (GILZ) in inflammatory bone loss.
Por: Nianlan Yang, et al.
Publicado em: (2017-01-01)

Endogenous Glucocorticoid Metabolism in Bone: Friend or Foe
Por: Claire S. Martin, et al.
Publicado em: (2021-08-01)

Individualizing the risks and benefits of postmenopausal hormone therapy.
Por: van Staa, T, et al.
Publicado em: (2008)

Epidemiology of fractures in England and Wales.
Por: van Staa, T, et al.
Publicado em: (2001)